Medison Pharma

PETACH TIKVAH, Israel, Nov 9, 2022 /PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, today announced the addition of South and Central America and the Caribbean markets ("Latin America") to its multi-territorial agreement with Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease

"The expansion of our partnership with Immunocore into LATAM is a significant milestone in building our unified commercial platform in all international markets," says Meir Jakobsohn, Founder and CEO of Medison "This in turn will allow us to fulfil our vision, ensuring that every patient in need will have fast access to highly innovative therapies in a wide range of international markets " "Our multi-regional platform makes us the partner-of-choice for emerging biotech companies seeking to make their innovative products available in international markets for the benefit of patients suffering from severe conditions", adds Gil Gurfinkel, VP Corporate Development at Medison "and the extension of Medison's multi-territorial agreement with Immunocore and expansion to Latin America, allows for a unique pairing between Immunocore's novel therapy and Medison's ability to commercialize and provide access to highly innovative therapies in international markets In this case, offering patients in Latin America hope in the form of a treatment for this rare and aggressive form of melanoma that affects the eye " Immunocore's KIMMTRAK® (tebentafusp-tebn), has been approved by the U S Food and Drug Administration (FDA), the European Medicines Agency (EMA), Australia Therapeutic Goods Administration (TGA) and Health Canada, and is the first and only treatment approved for patients with unresectable or metastatic uveal melanoma "